Chemical structure:

IUPAC name:

5-Chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine

CAS number:

202409-33-4

Therapy area:

NSAID

References:

IH/IP

Status:

Commercial scale

Mechanism of action

Etoricoxib is a COX-2 inhibitor which selectively inhibits isoform 2 of the enzyme cyclooxygenase (COX-2). It has approximately 106-fold selectivity for COX-2 inhibition over COX-1. This reduces the generation of prostaglandins (PGs) from arachidonic acid. Among the different functions exerted by PGs, their role in the inflammation cascade should be highlighted.

DISCLAIMER: PRODUCTS COVERED BY VALID & UNEXPIRED PATENTS ARE NOT OFFERED (OR) SUPPLIED FOR COMMERCIAL SCALE. THE PATENT POSITION SHOULD BE VERIFIED & LIABILITY LIES WITH THE CUSTOMER ONLY. PRODUCTS COVERED BY PATENTS ARE AVAILABLE ONLY FOR R&D USE.